TC
MYOV

TwinBeech Capital’s Myovant Sciences Ltd. MYOV Stock Holding History

TwinBeech Capital’s Portfolio MYOV Stock Details MYOV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-18,178
Closed -$255K – 670
2020
Q3 		$255K Buy
+18,178
New +$338K 0.06% 364

Other funds holding MYOV

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
PC
Pier Capital Stamford, Connecticut $606M AUM 63.41% 1-Year Est. Return

TwinBeech Capital's MYOV Position: Q4 2020 in Review

TwinBeech Capital sold out of Myovant Sciences Ltd. (MYOV) in Q4 2020, closing a stake of 18,178 shares — an estimated $255K sold.

TwinBeech Capital first reported a position in MYOV in Q3 2020 and held it in 1 quarter. The position peaked at $255K in Q3 2020. 105 funds tracked by Wall St. Rank hold MYOV as of Q4 2020.

  • TwinBeech Capital reported no remaining Myovant Sciences Ltd. position as of Q4 2020 after selling out during the quarter.
  • TwinBeech Capital sold 18,178 Myovant Sciences Ltd. shares in Q4 2020, an estimated $255K.
  • TwinBeech Capital first reported a position in Myovant Sciences Ltd. in Q3 2020 and held it in 1 quarter.
  • TwinBeech Capital's Myovant Sciences Ltd. position peaked at $255K in Q3 2020.
  • 105 funds tracked by Wall St. Rank held Myovant Sciences Ltd. as of Q4 2020.

Based on TwinBeech Capital's 13F filing for Q4 2020, filed 16 Feb 2021.